Testimony before the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding Tanezumab for Treatment of Osteoarthritis

View as PDF

In testimony before a joint meeting of the Food and Drug Administration’s (FDA’s) Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve tanezumab for treatment of osteoarthritis because the drug fails to provide clinically meaningful benefit compared with either placebo or oral non-steroidal anti-inflammatory drugs, but does dramatically increase the rates of rapidly progressive osteoarthritis and of total joint replacements in a dose- and duration-dependent manner.

See Public Citizen’s other work on the anti-nerve growth factor drug tanezumab.